Depomed pads pain portfolio with Xanodyne's Zipsor
This article was originally published in Scrip
Executive Summary
California-based Depomed has acquired all rights to Zipsor (diclofenac potassium), Xanodyne Pharmaceuticals' $19 million a year pain relief drug.